Qsymia clinical trials results
Jin Hee Shin, 1 Kishore M Gadde2
1Department of Community and Family Medicine, Duke University Medical Center, 2Obesity Clinical Trials Program, Duke University Medical Center, Durham, NC, USA
Abstract: Qsymia™ (Vivus Inc, Mountain View, CA, USA), a combination of phentermine and delayed-release topiramate, has been available in the US since September 2012 for the treatment of obesity. Phentermine is an anorexigenic agent, which is approved for the short-term treatment of obesity, while topiramate is approved for nonweight loss indications – seizure disorders and migraine prophylaxis. The amount of weight loss achieved with combination therapy is of a greater magnitude than what could be achieved with either agent alone. Adverse events that occur with the combination therapy are in line with the known side effect profiles of the constituent drugs; teratogenicity, a slight increase in heart rate, psychiatric and cognitive adverse effects, and metabolic acidosis are concerns.
Keywords: Qsymia, combination drug, antiobesity drugs, phentermine, topiramate, obesity, weight lossDownload Article [PDF]
You might also like
Saw Palmetto 160mg 120 Softgels
Health and Beauty (Physiologics)
BMC Medical Research Methodology at the 35th Annual Conference of the .. — BMC Pediatrics
The conference will focus on issues such as design and analysis of clinical trials, methods in biostatistics and development of clinical prediction models.
What were the clinical results of the tuskegee study?
The results of the Tuskegee study are actually quite broad and too in depth to put into the text message character limit.